Network analysis of human liver biopsies separates what simvastatin and ezetimibe do
- Patients on simvastatin, ezetimibe, the combination or placebo for four weeks before cholecystectomy gave liver transcriptomic and methylation data, integrated with plasma and bile biochemistry.
- Interpretable multimodal networks gave distinct molecular signatures for each treatment and highlighted apolipoprotein-centred modules.
- Predicted effects on APOA2 and PTPRS were partly confirmed in a hepatocyte-like cell model.
💡 Points Based on the abstract
Randomised human liver tissue on a marketed drug is rare and valuable, and it tells us how far cell-line mechanisms carry over. The weak link is validation: a hepatocyte-like line is a thin test of network predictions, and no outcome data connect PTPRS or APOA2 changes to lipid lowering. I would test whether these hits behave as pharmacodynamic biomarkers across other statins.
📄 Paper · British Journal of Pharmacology ↗ Interpretable multimodal network analysis of lipid-lowering therapies